About the Authors
- Henrica M. J. Werner
-
* E-mail: Henrica.Werner@k2.uib.no
Affiliations Centre for Cancer Biomarkers, Department of Clinical Science, The University of Bergen, Bergen, Norway, Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway
- Jone Trovik
-
Affiliations Centre for Cancer Biomarkers, Department of Clinical Science, The University of Bergen, Bergen, Norway, Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway
- Mari K. Halle
-
Affiliation Centre for Cancer Biomarkers, Department of Clinical Science, The University of Bergen, Bergen, Norway
- Elisabeth Wik
-
Affiliations Centre for Cancer Biomarkers, Department of Clinical Science, The University of Bergen, Bergen, Norway, Department of Pathology, Haukeland University Hospital, Bergen, Norway
- Lars A. Akslen
-
Affiliations Centre for Cancer Biomarkers, Department of Clinical Medicine, The University of Bergen, Bergen, Norway, Department of Pathology, Haukeland University Hospital, Bergen, Norway
- Even Birkeland
-
Affiliation Centre for Cancer Biomarkers, Department of Clinical Science, The University of Bergen, Bergen, Norway
- Therese Bredholt
-
Affiliation Centre for Cancer Biomarkers, Department of Clinical Science, The University of Bergen, Bergen, Norway
- Ingvild L. Tangen
-
Affiliations Centre for Cancer Biomarkers, Department of Clinical Science, The University of Bergen, Bergen, Norway, Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway
- Camilla Krakstad
-
Affiliation Centre for Cancer Biomarkers, Department of Clinical Science, The University of Bergen, Bergen, Norway
- Helga B. Salvesen
-
Affiliations Centre for Cancer Biomarkers, Department of Clinical Science, The University of Bergen, Bergen, Norway, Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway
Competing Interests
The authors report the following conflicts: The University of Bergen/Haukeland University Hospital/Dana Farber Cancer Institute/Harvard through BTO (Bergen Teknologioverføring AS): Some aspects relating to STMN1 as prognostic and predictive marker for endometrial cancer are subject to pending intellectual property rights (US 12/962,946). This does not alter the authors' adherence to the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: HMJW JT CK HBS. Performed the experiments: HMJW JT ILT EW EB TB MKH CK. Analyzed the data: HMJW JT EW MKH TB CK HBS. Contributed reagents/materials/analysis tools: HBS LAA EB CK, EW. Wrote the paper: HMJW CK JT HBS ILT EW EB TB MKH LAA.